Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.47 |
| ▸ | PPARG | P37231 | 10/20 | 0.47 |
| ▸ | PPARA | Q07869 | 9/20 | 0.47 |
| ▸ | GCG | P01275 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13791565 | 0.92 | PPARG (0.47) | PPARDPPARGPPARAGCGPARP1 | |
| SCHEMBL5904895 | 0.86 | PPARD (0.51) | PPARDPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL5904900 | 0.86 | PPARD (0.51) | PPARDPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL3964891 | 0.86 | PPARD (0.54) | PPARDPPARA | |
| SCHEMBL3960614 | 0.86 | PPARD (0.56) | PPARDPPARGPPARAGCGFFAR1 | |
| SCHEMBL5708243 | 0.85 | PPARD (0.40) | PPARDPPARGPPARAGCGFFAR1 | |
| SCHEMBL5708221 | 0.83 | PPARD (0.40) | PPARDPPARGPPARAPARP1 | |
| SCHEMBL5708198 | 0.83 | PPARD (0.48) | PPARDPPARGPPARA | |
| SCHEMBL3964896 | 0.82 | PPARA (0.41) | PPARDPPARGPPARAGCGPARP1 | |
| SCHEMBL3964320 | 0.81 | PPARD (0.47) | PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | claimed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | PPARD, PPARA, PPARG | PPARD 1/4885PPARG 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.